Welcome to LookChem.com Sign In|Join Free
  • or
1,4-Benzodioxan-2-methylamine, N-methyl-, also known as N-methyl-1,4-benzodioxan-2-methylamine, is a chemical compound with the molecular formula C9H11NO2. It is a derivative of the benzodioxane structure, featuring a methylamine group at the 2-position. 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYLis utilized in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and research chemicals. Its structural similarity to certain neurotransmitters and psychoactive compounds suggests potential applications in neuroscience and pharmacology. However, it is crucial to handle this chemical with care due to possible health and safety risks associated with its use.

2242-31-1

Post Buying Request

2242-31-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2242-31-1 Usage

Uses

Used in Organic Synthesis:
1,4-Benzodioxan-2-methylamine, N-methylis used as a building block in organic synthesis for the creation of various pharmaceuticals and research chemicals. Its unique structure allows for the development of new compounds with potential therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1,4-Benzodioxan-2-methylamine, N-methylserves as a key intermediate in the synthesis of drugs. Its incorporation into drug molecules can enhance their pharmacological activity and selectivity.
Used in Neuroscience Research:
Due to its structural resemblance to neurotransmitters and psychoactive compounds, 1,4-Benzodioxan-2-methylamine, N-methylmay be used in neuroscience research to study the interactions of these compounds with biological systems and to develop new treatments for neurological disorders.
Used in Pharmacology:
In pharmacology, 1,4-Benzodioxan-2-methylamine, N-methylcould be employed to investigate the mechanisms of action of psychoactive substances and to design new drugs with improved efficacy and safety profiles.

Check Digit Verification of cas no

The CAS Registry Mumber 2242-31-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,4 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2242-31:
(6*2)+(5*2)+(4*4)+(3*2)+(2*3)+(1*1)=51
51 % 10 = 1
So 2242-31-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO2/c1-11-6-8-7-12-9-4-2-3-5-10(9)13-8/h2-5,8,11H,6-7H2,1H3

2242-31-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-methylmethanamine

1.2 Other means of identification

Product number -
Other names Methylaminomethylbenzodioxan

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2242-31-1 SDS

2242-31-1Relevant academic research and scientific papers

Novel, broad-spectrum anticonvulsants containing a sulfamide group: Pharmacological properties of (S)- N -[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2- yl)methyl]sulfamide (JNJ-26489112)

McComsey, David F.,Smith-Swintosky, Virginia L.,Parker, Michael H.,Brenneman, Douglas E.,Malatynska, Ewa,White, H. Steve,Klein, Brian D.,Wilcox, Karen S.,Milewski, Michael E.,Herb, Mark,Finley, Michael F. A.,Liu, Yi,Lubin, Mary Lou,Qin, Ning,Reitz, Allen B.,Maryanoff, Bruce E.

, p. 9019 - 9030 (2014/01/06)

Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.

USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY

-

Page/Page column 16, (2009/10/06)

The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I)

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN

-

Page/Page column 15, (2008/06/13)

The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as desc

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS

-

Page/Page column 21, (2008/06/13)

The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use

CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS

-

Page/Page column 37-38, (2008/06/13)

The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS

-

Page/Page column 16, (2010/11/27)

The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS

-

Page/Page column 14, (2010/11/27)

The present invention is a methods for neuroprotection, for treating an acute neurodegenerative disorder, for treating a chronic neurodegenerative disorder and/or for preventing neuron death or damage following brain, head and/or spinal cord trauma or inj

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION

-

Page/Page column 14, (2010/11/27)

The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I

USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER

-

Page/Page column 16-17, (2010/11/27)

The present invention is a method for the treatment of mania and/or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I)

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

-

Page/Page column 15, (2010/11/27)

The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) a

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2242-31-1